- Home
- AGEN vs BCV Comparison
AGEN vs BCV Comparison
Compare AGEN & BCV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGEN
- BCV
- Stock Information
- Founded
- AGEN 1994
- BCV 1971
- Country
- AGEN United States
- BCV United States
- Employees
- AGEN N/A
- BCV N/A
- Industry
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- BCV Finance/Investors Services
- Sector
- AGEN Health Care
- BCV Finance
- Exchange
- AGEN Nasdaq
- BCV Nasdaq
- Market Cap
- AGEN 96.2M
- BCV 106.0M
- IPO Year
- AGEN 2000
- BCV N/A
- Fundamental
- Price
- AGEN $3.83
- BCV $18.28
- Analyst Decision
- AGEN Buy
- BCV
- Analyst Count
- AGEN 3
- BCV 0
- Target Price
- AGEN $10.50
- BCV N/A
- AVG Volume (30 Days)
- AGEN 399.9K
- BCV 26.3K
- Earning Date
- AGEN 03-13-2025
- BCV 01-01-0001
- Dividend Yield
- AGEN N/A
- BCV 8.13%
- EPS Growth
- AGEN N/A
- BCV N/A
- EPS
- AGEN N/A
- BCV N/A
- Revenue
- AGEN $160,427,000.00
- BCV N/A
- Revenue This Year
- AGEN N/A
- BCV N/A
- Revenue Next Year
- AGEN $36.13
- BCV N/A
- P/E Ratio
- AGEN N/A
- BCV N/A
- Revenue Growth
- AGEN 59.00
- BCV N/A
- 52 Week Low
- AGEN $2.50
- BCV $14.09
- 52 Week High
- AGEN $19.69
- BCV $18.11
- Technical
- Relative Strength Index (RSI)
- AGEN 65.58
- BCV 56.64
- Support Level
- AGEN $3.08
- BCV $17.78
- Resistance Level
- AGEN $3.29
- BCV $18.03
- Average True Range (ATR)
- AGEN 0.27
- BCV 0.29
- MACD
- AGEN 0.08
- BCV 0.02
- Stochastic Oscillator
- AGEN 94.84
- BCV 76.35
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About BCV Bancroft Fund Ltd.
Bancroft Fund Ltd is a diversified closed-end management company. It operates as a closed-ended equity mutual fund. The funds' main objective is to provide income and potential for capital appreciation. With the intent to achieve its objective, the company invests in convertible and equity securities. It invests across different industries such as Computer Software and Services, Energy and Utilities, Health Care among others.